Literature DB >> 28814408

Intrinsic Maturational Neonatal Immune Deficiencies and Susceptibility to Group B Streptococcus Infection.

Michelle L Korir1, Shannon D Manning1, H Dele Davies2.   

Abstract

Although a normal member of the gastrointestinal and vaginal microbiota, group B Streptococcus (GBS) can also occasionally be the cause of highly invasive neonatal disease and is an emerging pathogen in both elderly and immunocompromised adults. Neonatal GBS infections are typically transmitted from mother to baby either in utero or during passage through the birth canal and can lead to pneumonia, sepsis, and meningitis within the first few months of life. Compared to the adult immune system, the neonatal immune system has a number of deficiencies, making neonates more susceptible to infection. Recognition of GBS by the host immune system triggers an inflammatory response to clear the pathogen. However, GBS has developed several mechanisms to evade the host immune response. A comprehensive understanding of this interplay between GBS and the host immune system will aid in the development of new preventative measures and therapeutics.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  group B streptococcus; immunology; inflammation; prevention

Mesh:

Year:  2017        PMID: 28814408      PMCID: PMC5608877          DOI: 10.1128/CMR.00019-17

Source DB:  PubMed          Journal:  Clin Microbiol Rev        ISSN: 0893-8512            Impact factor:   26.132


  159 in total

1.  Differential expression of the B cell-restricted molecule CD22 on neonatal B lymphocytes depending upon antigen stimulation.

Authors:  D Viemann; P Schlenke; H J Hammers; H Kirchner; A Kruse
Journal:  Eur J Immunol       Date:  2000-02       Impact factor: 5.532

2.  CsrRS regulates group B Streptococcus virulence gene expression in response to environmental pH: a new perspective on vaccine development.

Authors:  Isabella Santi; Renata Grifantini; Sheng-Mei Jiang; Cecilia Brettoni; Guido Grandi; Michael R Wessels; Marco Soriani
Journal:  J Bacteriol       Date:  2009-06-19       Impact factor: 3.490

Review 3.  Neutrophil extracellular traps.

Authors:  Borko Amulic; Garret Hayes
Journal:  Curr Biol       Date:  2011-05-10       Impact factor: 10.834

4.  The Protective Value of Maternal Group B Streptococcus Antibodies: Quantitative and Functional Analysis of Naturally Acquired Responses to Capsular Polysaccharides and Pilus Proteins in European Maternal Sera.

Authors:  Monica Fabbrini; Fabio Rigat; C Daniela Rinaudo; Irene Passalaqua; Sceida Khacheh; Roberta Creti; Lucilla Baldassarri; Filippo Carboni; Giulia Anderloni; Roberto Rosini; Domenico Maione; Guido Grandi; John L Telford; Immaculada Margarit
Journal:  Clin Infect Dis       Date:  2016-07-11       Impact factor: 9.079

5.  BibA: a novel immunogenic bacterial adhesin contributing to group B Streptococcus survival in human blood.

Authors:  Isabella Santi; Maria Scarselli; Massimo Mariani; Alfredo Pezzicoli; Vega Masignani; Annarita Taddei; Guido Grandi; John L Telford; Marco Soriani
Journal:  Mol Microbiol       Date:  2007-01-08       Impact factor: 3.501

6.  Novel engagement of CD14 and multiple toll-like receptors by group B streptococci.

Authors:  P Henneke; O Takeuchi; J A van Strijp; H K Guttormsen; J A Smith; A B Schromm; T A Espevik; S Akira; V Nizet; D L Kasper; D T Golenbock
Journal:  J Immunol       Date:  2001-12-15       Impact factor: 5.422

Review 7.  Status of vaccine research and development of vaccines for GBS.

Authors:  Paul T Heath
Journal:  Vaccine       Date:  2016-03-15       Impact factor: 3.641

8.  Group B streptococci persist inside macrophages.

Authors:  P Cornacchione; L Scaringi; K Fettucciari; E Rosati; R Sabatini; G Orefici; C von Hunolstein; A Modesti; A Modica; F Minelli; P Marconi
Journal:  Immunology       Date:  1998-01       Impact factor: 7.397

9.  Nuclease A (Gbs0661), an extracellular nuclease of Streptococcus agalactiae, attacks the neutrophil extracellular traps and is needed for full virulence.

Authors:  Aurélie Derré-Bobillot; Naima G Cortes-Perez; Yuji Yamamoto; Pascale Kharrat; Elizabeth Couvé; Violette Da Cunha; Patrice Decker; Marie-Christophe Boissier; Frédéric Escartin; Bénédicte Cesselin; Philippe Langella; Luis G Bermúdez-Humarán; Philippe Gaudu
Journal:  Mol Microbiol       Date:  2013-07-05       Impact factor: 3.501

10.  Dual role of TLR2 and myeloid differentiation factor 88 in a mouse model of invasive group B streptococcal disease.

Authors:  Giuseppe Mancuso; Angelina Midiri; Concetta Beninati; Carmelo Biondo; Roberta Galbo; Shizuo Akira; Philipp Henneke; Douglas Golenbock; Giuseppe Teti
Journal:  J Immunol       Date:  2004-05-15       Impact factor: 5.422

View more
  5 in total

1.  Enhanced Postnatal Acquisition of Hypervirulent Group B Streptococcus.

Authors:  Adam J Ratner
Journal:  Clin Infect Dis       Date:  2019-10-30       Impact factor: 9.079

2.  Genetically distinct Group B Streptococcus strains induce varying macrophage cytokine responses.

Authors:  Rebecca A Flaherty; Elena C Borges; Jessica A Sutton; David M Aronoff; Jennifer A Gaddy; Margaret G Petroff; Shannon D Manning
Journal:  PLoS One       Date:  2019-09-19       Impact factor: 3.240

3.  Group B Streptococcus colonization induces Prevotella and Megasphaera abundance-featured vaginal microbiome compositional change in non-pregnant women.

Authors:  Xiaofeng Mu; Changying Zhao; Junjie Yang; Xiaofang Wei; Jiaming Zhang; Cheng Liang; Zhongtao Gai; Chunling Zhang; Dequan Zhu; Ye Wang; Lei Zhang
Journal:  PeerJ       Date:  2019-08-16       Impact factor: 2.984

Review 4.  A Vaccine Against Group B Streptococcus: Recent Advances.

Authors:  Clara Carreras-Abad; Laxmee Ramkhelawon; Paul T Heath; Kirsty Le Doare
Journal:  Infect Drug Resist       Date:  2020-04-29       Impact factor: 4.003

5.  Distinct Group B Streptococcus Sequence and Capsule Types Differentially Impact Macrophage Stress and Inflammatory Signaling Responses.

Authors:  Rebecca A Flaherty; David M Aronoff; Jennifer A Gaddy; Margaret G Petroff; Shannon D Manning
Journal:  Infect Immun       Date:  2021-04-16       Impact factor: 3.441

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.